Aculeus receives TIA Pipeline Accelerator Voucher to support STING program

MELBOURNE — (July 23, 2021) Aculeus Therapeutics is pleased to announce that it has received a Therapeutic Innovations Australia (TIA) Pipeline Accelerator Voucher to support work at the Centre for Drug Candidate Optimisation (CDCO).

CDCO has been an important scientific partner for the STING program over many years and their input is even more critical now as Aculeus approaches candidate selection. TIA supports translational research infrastructure to advance the development new therapeutics for human health.

For more information on TIA, visit: therapeuticinnovation.com.au